{
    "nct_id": "NCT06108050",
    "official_title": "A Phase 1, First-in-human, Open-label, Multicenter Study of JZP898 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "Inclusion Criteria\n\n* Adult ≥ 18 years of age\n* Histological or cytological diagnosis of advanced or metastatic solid tumor.\n\n  1. Previously treated participants with solid tumors (eg. NSCLC, melanoma, HNSCC, RCC, HCC, gastroesophageal carcinomas, UC, or CRC [MSI-H]) for whom, in the opinion of the investigator, there is no SoC available to convey clinical benefit.\n  2. Parts A2 and B: previously-treated (≥ 1 line of prior anticancer therapy) participants with select tumor types (NSCLC, HNSCC, melanomas, RCC, and UC) who have progressed on/after prior CPI therapy based on investigator assessment per RECIST version 1.1.\n* Participants in select tumor types:\n\n  1. NSCLC: eligible for platinum-based therapy and received platinum-based therapy prior to inclusion in the study.\n  2. HNSCC: eligible for platinum therapy and received platinum-based therapy prior to inclusion in this study.\n  3. Melanoma with known BRAFv600 mutation: received BRAF/MEKi therapy before this study.\n* ECOG score of 0 to 1.\n* Measurable disease per RECIST version 1.1 criteria.\n* Parts A1 and A2 only: willing to consent to mandatory tumor biopsies (both pretreatment and post-treatment with JZP898) unless medically infeasible\n* Adequate organ and bone marrow function as indicated by the following laboratory values (within 4 weeks prior to starting the study interventions)\n* Men and women of reproductive potential to observe highly effective birth control for the duration of treatment and for 4 months following the last dose of study drug;\n* Additional criteria may apply\n\nExclusion Criteria\n\n* Unresolved toxicities > Grade 1.\n* Hypersensitivity to mAb, IFNα, or study intervention components.\n* Primary CNS tumor or symptomatic CNS metastases.\n* Have a second primary malignancy treated within the previous 2 years (exceptions: non-metastatic, non-melanomatous skin cancers, carcinoma in-situ, and melanoma in-situ).\n* Active autoimmune disease (in the last 2 years) requiring systemic steroids or immunosuppressive agents.\n* Active or history of pneumonitis (noninfectious) or interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.\n* Any history of suicidal behavior or any suicidal ideation\n* Clinically significant ischemic/hemorrhagic cerebrovascular accident/stroke and/or clinically significant active cardiovascular disease\n* Received any anticancer therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug\n* Received prior radiotherapy within 2 weeks of the first dose of study drug or have had a history of radiation pneumonitis\n* Major surgery within 2 weeks prior to the first dose of study intervention.\n* Participant is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study\n* Had an allogeneic tissue/solid organ transplant.\n* Receipt of prior IFNα therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}